At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 102 enrolled
Drug / intervention
brentuximab vedotindrug
Likely dose
brentuximab vedotin 1.8 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pivotal Study of SGN-35 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL)
In Brief
A Phase 2 clinical trial evaluating brentuximab vedotin for Disease, Hodgkin. Completed, enrolled 102 participants across 27 sites in 5 countries.
Detailed Summary
This is a single-arm, open-label, multicenter, pivotal clinical trial to evaluate the efficacy and safety of brentuximab vedotin (SGN-35) as a single agent in patients with relapsed or refractory Hodgkin lymphoma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDisease, Hodgkin
CountriesBelgium, Canada, France, Italy, United States
CollaboratorsMillennium Pharmaceuticals, Inc.
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2009
First PostedFeb 2009
Primary CompletionAug 2010
Study CompletionMay 2015
TodayJul 2026
First PostedFeb 20, 2009
Enrollment StartFeb 1, 2009
Primary CompletionAug 1, 2010
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 17.4 years ago
Interventions
brentuximab vedotindrug
1.8 mg/kg every 3 weeks by intravenous infusion